Development of IGF-IR inhibitors in pediatric sarcomas

E. Anders Kolb, Richard Gorlick

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

For approximately two decades, the insulin-like growth factor (IGF) has been implicated in the pathogenesis of numerous pediatric malignancies, including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma. In the past, major toxicities have limited the clinical development of IGF-targeted therapies. However, recent interest has been heightened by the availability of increasingly specific small molecules and antibodies directed at IGF-I receptor. Preclinical data using these inhibitors against xenograft models of pediatric sarcomas, coupled with responses in adults with Ewing sarcoma, have generated significant excitement about the clinical potential of this class of drugs and have driven the rapid development of numerous clinical trials now under way. This article reviews the preclinical data and the ongoing clinical trials, as well as issues regarding the further development of these drugs specifically for pediatric malignancies.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalCurrent Oncology Reports
Volume11
Issue number4
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Somatomedins
Sarcoma
Ewing's Sarcoma
Pediatrics
Clinical Trials
IGF Type 1 Receptor
Rhabdomyosarcoma
Osteosarcoma
Heterografts
Pharmaceutical Preparations
Neoplasms
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Development of IGF-IR inhibitors in pediatric sarcomas. / Kolb, E. Anders; Gorlick, Richard.

In: Current Oncology Reports, Vol. 11, No. 4, 2009, p. 307-313.

Research output: Contribution to journalArticle

Kolb, E. Anders ; Gorlick, Richard. / Development of IGF-IR inhibitors in pediatric sarcomas. In: Current Oncology Reports. 2009 ; Vol. 11, No. 4. pp. 307-313.
@article{937e7999e1b94efea2e48de6a6480248,
title = "Development of IGF-IR inhibitors in pediatric sarcomas",
abstract = "For approximately two decades, the insulin-like growth factor (IGF) has been implicated in the pathogenesis of numerous pediatric malignancies, including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma. In the past, major toxicities have limited the clinical development of IGF-targeted therapies. However, recent interest has been heightened by the availability of increasingly specific small molecules and antibodies directed at IGF-I receptor. Preclinical data using these inhibitors against xenograft models of pediatric sarcomas, coupled with responses in adults with Ewing sarcoma, have generated significant excitement about the clinical potential of this class of drugs and have driven the rapid development of numerous clinical trials now under way. This article reviews the preclinical data and the ongoing clinical trials, as well as issues regarding the further development of these drugs specifically for pediatric malignancies.",
author = "Kolb, {E. Anders} and Richard Gorlick",
year = "2009",
doi = "10.1007/s11912-009-0043-1",
language = "English (US)",
volume = "11",
pages = "307--313",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Development of IGF-IR inhibitors in pediatric sarcomas

AU - Kolb, E. Anders

AU - Gorlick, Richard

PY - 2009

Y1 - 2009

N2 - For approximately two decades, the insulin-like growth factor (IGF) has been implicated in the pathogenesis of numerous pediatric malignancies, including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma. In the past, major toxicities have limited the clinical development of IGF-targeted therapies. However, recent interest has been heightened by the availability of increasingly specific small molecules and antibodies directed at IGF-I receptor. Preclinical data using these inhibitors against xenograft models of pediatric sarcomas, coupled with responses in adults with Ewing sarcoma, have generated significant excitement about the clinical potential of this class of drugs and have driven the rapid development of numerous clinical trials now under way. This article reviews the preclinical data and the ongoing clinical trials, as well as issues regarding the further development of these drugs specifically for pediatric malignancies.

AB - For approximately two decades, the insulin-like growth factor (IGF) has been implicated in the pathogenesis of numerous pediatric malignancies, including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma. In the past, major toxicities have limited the clinical development of IGF-targeted therapies. However, recent interest has been heightened by the availability of increasingly specific small molecules and antibodies directed at IGF-I receptor. Preclinical data using these inhibitors against xenograft models of pediatric sarcomas, coupled with responses in adults with Ewing sarcoma, have generated significant excitement about the clinical potential of this class of drugs and have driven the rapid development of numerous clinical trials now under way. This article reviews the preclinical data and the ongoing clinical trials, as well as issues regarding the further development of these drugs specifically for pediatric malignancies.

UR - http://www.scopus.com/inward/record.url?scp=67649389647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649389647&partnerID=8YFLogxK

U2 - 10.1007/s11912-009-0043-1

DO - 10.1007/s11912-009-0043-1

M3 - Article

C2 - 19508836

AN - SCOPUS:67649389647

VL - 11

SP - 307

EP - 313

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 4

ER -